Post the receipt of FDA approval in June, QIAGEN (QGEN - Free Report) recently announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States. The advanced test kit will be available from Oct 9.
Built on the QuantiFERON-TB Gold (QFT) platform, QFT-Plus will provide enhanced analysis of TB infection. This advanced kit makes TB testing with innovative antigens possible as it measures the cell-mediated immune response to TB from both CD4+ and CD8+ T cells.
Per the company, roughly 93% of the disease in the United States originates from the 13 million-person reservoir of latent TB infection. This highlights the significance of the availability of a testing kit like QFT-Plus.
The launch is likely to widen QIAGEN’s customer base in the huge TB testing market. Per a Morbidity and Mortality Weekly Report (MMWR) published by Centers for Disease Control and Prevention, a total of 9,287 new TB cases were diagnosed in the United States in 2016. And according to Research and Markets data published in Business Wire, TB market is expected to see a CAGR of 4.3% to 4.8% between 2016 and 2022.
The QFT-Plus test kit falls under the company’s Molecular Diagnostics segment which was the highest revenue grosser in the last reported quarter. Notably, the segment contributed 48% to total revenues on the back of substantial growth in QuantiFERON latent TB tests, QIAsymphony automation system consumables portfolio and Personalized Healthcare.
Share Price Performance
QIAGEN has been gaining investor confidence on consistently encouraging results. Over the last six months, the company’s share price has outperformed the broader industry. The stock has gained 17.1%, as compared to the broader industry’s 12.1% gain. The company has also surpassed the 3.6% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
QIAGENcurrently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International and Luminex sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 9.2% over the last three months.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock gained 7.4% last month.
IDEXX Laboratorieshas a long-term expected earnings growth rate of 19.8%. The stock has gained 37.1% in the last year.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Post the receipt of FDA approval in June, QIAGEN (QGEN - Free Report) recently announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States. The advanced test kit will be available from Oct 9.
Built on the QuantiFERON-TB Gold (QFT) platform, QFT-Plus will provide enhanced analysis of TB infection. This advanced kit makes TB testing with innovative antigens possible as it measures the cell-mediated immune response to TB from both CD4+ and CD8+ T cells.
Per the company, roughly 93% of the disease in the United States originates from the 13 million-person reservoir of latent TB infection. This highlights the significance of the availability of a testing kit like QFT-Plus.
The launch is likely to widen QIAGEN’s customer base in the huge TB testing market. Per a Morbidity and Mortality Weekly Report (MMWR) published by Centers for Disease Control and Prevention, a total of 9,287 new TB cases were diagnosed in the United States in 2016. And according to Research and Markets data published in Business Wire, TB market is expected to see a CAGR of 4.3% to 4.8% between 2016 and 2022.
The QFT-Plus test kit falls under the company’s Molecular Diagnostics segment which was the highest revenue grosser in the last reported quarter. Notably, the segment contributed 48% to total revenues on the back of substantial growth in QuantiFERON latent TB tests, QIAsymphony automation system consumables portfolio and Personalized Healthcare.
Share Price Performance
QIAGEN has been gaining investor confidence on consistently encouraging results. Over the last six months, the company’s share price has outperformed the broader industry. The stock has gained 17.1%, as compared to the broader industry’s 12.1% gain. The company has also surpassed the 3.6% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
QIAGENcurrently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International and Luminex sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 9.2% over the last three months.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock gained 7.4% last month.
IDEXX Laboratorieshas a long-term expected earnings growth rate of 19.8%. The stock has gained 37.1% in the last year.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on OFIX - FREE
Get the latest research report on QGEN - FREE
Get the latest research report on IDXX - FREE